Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance by Shi , Haifei & Senthil Kumar, Shiva Priya Dharshan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4 
 
 
 
 
© 2012 Shi and Kumar, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Sex Differences in Obesity-Related Glucose 
Intolerance and Insulin Resistance 
Haifei Shi and Shiva Priya Dharshan Senthil Kumar 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/52972 
1. Introduction 
The prevalence of obesity has increased dramatically over the past decade (1) along with 
several health risks it encompasses, including non-insulin dependent type 2 diabetes, 
cardiovascular disease, fatty liver, dyslipidemia, and some types of cancer (2). The economic 
costs of caring for patients with obesity and diabetic complications are enormously high (3). 
There are important sex differences in the prevalence of these metabolic diseases. 
Premenopausal women have much less metabolic disorders than men; however, the 
prevalence of obesity and diabetes increases dramatically in postmenopausal women (4). 
Sex steroid hormone estrogen may be protective against the metabolic syndrome and may 
contribute to the maintenance of insulin sensitivity, and its deficiency leads to development 
of type 2 diabetes and insulin resistance. This has resulted in the use of estrogen hormone 
replacement therapy for the treatment of insulin resistance in postmenopausal women (5) 
and in men with congenital aromatase deficiency (6). Thus, estrogen has enormous potential 
as a therapeutic agent for use in the prevention or treatment of type 2 diabetes with glucose 
intolerance and insulin resistance. 
1.1. Sex differences in genetic polymorphisms on the development of diabetes 
The development and etiology of obesity and related diseases such as type 2 diabetes stems 
from a conflict between genes which allowed our ancestors to survive extended periods of 
famine and physiological responses to caloric excess and sedentary lifestyle of the modern 
world. Some studies have evaluated potential genetic components and reported sex 
differences in the effects of certain polymorphisms of several enzymes and genes on the 
development and etiology of diabetes. Several examples are listed below. 
First example is protein tyrosine phosphatase, an enzyme involving signal transduction of T 
cell and insulin receptors. The activity of this enzyme, affected by certain genotypes, is 
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related to age of onset of type 1 diabetes in a sex-specific manner (7). Specifically, genotypes 
associated with medium to high enzyme activity are correlated with younger age of onset in 
females but not in males, whereas low activity genotypes do not display sex differences. 
Second example is peroxisome proliferator-activated receptor y2 (PPARy2), whose 
polymorphism is correlated with increased insulin sensitivity and reduced risk for type 2 
diabetes. Interestingly, in males, a more efficient shift from lipid oxidation in the basal state 
to carbohydrate oxidation during insulin stimulation has been observed in lean, glucose 
tolerant males with the polymorphism compared to wild-type males; whereas this 
difference has not been observed in females (8). Therefore, the PPARy2 polymorphism 
protects individuals from insulin insensitivity by promoting better suppression of lipid 
oxidation leading to more glucose disposal in males but not females. Another example is the 
3’ untranslated region of the PPP1R3A gene, a gene involved in glycogen synthase activity 
and associated with development of type 2 diabetes (9). Males homozygous for the 
polymorphism of PPP1R3A gene are significantly younger at diagnosis than female carriers 
(10). Additionally, a polymorphism in the promoter region of uncoupling protein (UCP)-2, a 
mitochondrial inner membrane protein, may be involved in obesity and development of 
type 2 diabetes (11). In a study of 100 obese subjects, the genotype that causes increased 
transcription of UCP-2 mRNA is more prevalent in diabetic women than in nondiabetic 
women. However no difference in distribution of this genotype is detected in men (12). To 
summarize, sex differences in genetic polymorphisms exist in the development and etiology 
of diabetes.  
1.2. Sex differences in physiologic mechanism on the development of diabetes 
Obesity has been recognized as a major and an independent diabetes risk factor. The 
increase in type 2 diabetes is closely associated with the epidemic of obesity. Body 
composition is very closely associated with glucose tolerance and insulin sensitivity (13). 
Development of adverse metabolic complications has been attributed to increased body fat, 
not just body weight, and the fat distributed particularly in the abdominal visceral 
compartment, a source of bioactive mediators that directly contribute to insulin resistance 
(14). To be more specific, intra-abdominal visceral adipose tissue carries a stronger risk for 
the development of metabolic disorders, such as glucose intolerance and insulin resistance 
related type 2 diabetes, than subcutaneous adipose tissue. Therefore, risk for diabetes 
incidence is particularly high in individuals with large amounts of abdominal visceral fat.  
Sex differences in the regional fat distribution exist. Males and females differ in terms of 
how and where they store body fat. In humans, premenopausal women usually have more 
subcutaneous fat, whereas men have more intra-abdominal visceral fat. Consequently, 
obesity-related metabolic disorders are much lower in premenopausal women than men 
(15). In addition, estrogens are responsible for body weight homeostasis in women. The 
prevalence of obesity is particularly high among middle-aged women. Symptoms of the 
metabolic syndrome, including increased visceral obesity and shifts in body fat distribution, 
as well as glucose intolerance and insulin resistance begin appearing in many women 
experiencing menopause and developing estrogen deficiency (16). Even in women who do 
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not gain weight after menopause, fat shifts from a subcutaneous location into the abdomen. 
Women are at an increased risk to develop visceral obesity due to the loss of endogenous 
ovarian hormone production. The increased visceral obesity in menopausal women can be 
altered by exogenous hormone replacement therapy (17, 18). Researches using animal 
models have provided important insights into the pathogenesis of human diseases and new 
therapeutic approaches. Peripheral metabolic signals and hormones are not only involved in 
regulating adiposity and body fat distribution, but also involved in regulating glucose 
metabolism and glucose tolerance. In experimental rodent models, reductions in circulating 
estrogens, which occurs following removal of ovaries (i.e., ovariectomy), results in increased 
body adiposity. Such increase in body adiposity can be ameliorated by exogenous 17β –
estradiol administration (19).  
In addition, sex hormones are directly involved in the regulation of glucose tolerance (20, 
21). In a prospective study that included over 500 women and men who did not have 
diabetes upon study entry, development of diabetes was associated with low levels of total 
testosterone in men and high levels of bioavailable testosterone in women (22). Therefore, 
differences in the regulation of glucose tolerance may be under the influence of sex 
hormones indirectly through their influence of body fat content and distribution or directly 
through their influence in the glucose metabolism and insulin signaling.  
This chapter discusses the sex differences in regulation of glucose homeostasis, focusing on 
the roles of female sex hormone estrogens as determinants mediating body adiposity levels 
and body fat distribution as well as glucose metabolism and insulin sensitivity. We will use 
the term “sex difference” instead of “gender difference” throughout this chapter. The term 
“sex” refers to differences between males and females that result from the chromosomal 
complement and the effects of hormones; whereas the term “gender” refers to an 
individual’s identity as a man or a woman, and the cultural and behavioral expectations 
associated with being a man or a woman. With regard to the regulation of glucose 
homeostasis and energy metabolism, little is known about gender differences, thus this 
chapter focuses primarily on sex differences. 
2. Sex differences in body adiposity and fat distribution 
The prevalence of obesity is higher in women than in men in many areas around the world 
(www.iaso.org). In addition there is a sex difference in body fat distribution. These sex 
differences in obesity incidence and fat distribution can be explained in part by the influence 
of gonadal steroids, as well as behavioral, socio-cultural and genetic factors. Several factors 
may play important roles to drive greater propensity for excess body fat in females than in 
males. It has been suggested that evolutionary pressures predispose females to store excess 
fat for reproduction and lactation. In contrast, evolutionary pressures predispose males to 
burn stored fuels in gathering and hunting. Adipose tissue plays a major role in the 
regulation of glucose homeostasis and insulin sensitivity, thus total body adiposity is closely 
associated with insulin sensitivity. Increased body fat is a risk factor for developing type 2 
diabetes mellitus. A line of research has focused on behavioral and social differences 
between men and women that relate to eating or activity behaviors. Sex differences in body 
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composition and insulin sensitivity are evident in humans throughout the lifespan. 
Pregnancy and menopause also have physiological and behavioral consequences on 
appetite and weight regulation that confer elevated obesity risk in many women. There is a 
sex difference in the regional fat distribution. Men and premenopausal women differ in their 
fat distribution. Females have “gynoid” or female-pattern fat distribution with more 
subcutaneous fat, whereas males have “android” or male-pattern body fat distribution with 
more abdominal visceral fat (15). Fat deposition in the subcutaneous depot is important for 
females during lactation. Despite the higher level of body fat, obesity-related metabolic 
disorders, such as type 2 diabetes, are much lower in premenopausal women and female 
animals than males. The role of estrogen in mediating body fat distribution and glucose 
homeostasis will be discussed in this chapter. 
2.1. Difference between subcutaneous and abdominal adipose tissues 
Body fat distribution is a more appropriate indicator than total adiposity for metabolic 
disorders, as obesity is not only a condition characterized by homogenous distribution of 
adipose tissue, but that the regional distribution of adipose tissue is more important in 
understanding the relationship between obesity and various metabolic diseases. Adipose 
tissue, which is distributed in the abdominal viscera, carries a greater risk for glucose 
intolerance and insulin resistance than adipose tissue subcutaneously. Specifically, 
abdominal adipose tissues contribute to the development of insulin resistance, glucose 
intolerance, hypertension, dyslipidemia, and atherosclerosis (23). Metabolites and secretions 
of visceral adipose tissue drain through the hepatic portal system, partially at least, to the 
liver. Insulin effect is lower and catecholamine effect is higher in visceral than subcutaneous 
adipose tissue. Specifically,  visceral fat have higher rates of catecholamine-induced lipolysis 
(24, 25), express higher numbers of beta-1, -2 and -3 adrenergic receptors and are more 
sensitive to catecholamine-induced lipolysis  (26, 27), and are less responsive to the cAMP-
lowering effects of alpha-adrenergic agonists (28). In addition, visceral fat cells express 
higher levels of glucocorticoid receptor (29, 30) and have greater glucocorticoid response 
with lipoprotein lipase activation (31), produce more angiotensinogen (32, 33), and secrete 
more interleukin-6 and plasminogen activator inhibitor-1 (34) than subcutaneous adipose 
tissue. Accumulation of intra-abdominal/visceral adipose tissue carries a much greater risk 
for metabolic disorders than does adipose tissue distributed subcutaneously (35-37). In 
contrast, subcutaneous fat distribution is poorly correlated with risks for these metabolic 
disorders (23). Therefore, the elevated health risks in diabetes associated with obesity 
depend on the localization of the adipose tissue in the body, as the distribution of fat is more 
directly associated with glucose tolerance and insulin sensitivity than the total body 
adiposity. Consequently, there is a sex-based difference in the prevalence and incidence of 
metabolic complications associated with obesity. Males have an increased incidence of 
obesity-related metabolic diseases than females aged 12 to 18 years (38, 39). In 
premenopausal women, there is a lower incidence of metabolic disorders associated with 
obesity (38). The prevalence of the metabolic syndrome increases with age, and the 
prevalence of the metabolic syndrome is similar in middle-aged men and women (40). 
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There are noted functional differences between subcutaneous and abdominal adipose 
tissues. Subcutaneous tissue is poorly innervated compared to the abdominal adipose tissue 
(35). Consequently, subcutaneous adipose tissue takes up free fatty acids and stores the 
excess calories more readily than abdominal adipose tissue in both males and females. 
Lipoprotein lipase (LPL) is the major enzyme involved in the fatty acid uptake and is the 
key regulator of fat accumulation in adipose tissues. Estrogens decrease adipose tissue LPL 
activity (41-43), and thus males have a higher level of LPL activity and thus fat accumulation 
than females with higher levels of estrogens. The lipolytic pathway involves the breakdown of 
energy stored in the form of triglycerides and is initiated when the energy supply from the 
metabolic fuels is depleted. The lipolytic activity of the abdominal fat is higher compared to 
the lipolytic activity of the subcutaneous fat in premenopausal women; a phenomenon not 
observed in post-menopausal women lacking endogenous estrogen (24, 44, 45).  
Recent evidence suggests that great subcutaneous fat accumulation may be protective 
against development of metabolic disorders. First, epidemiological studies indicate 
association of a high waist-to-hip ratio, instead of a large waist circumference alone, with 
the incidence of type 2 diabetes and other metabolic diseases (46-48). Indeed, a larger hip 
circumference has been shown to be protective against metabolic risk in multiple ethnic 
groups, independent of waist circumference or abdominal fat accumulation(49). Second, 
several animal studies reported that mice with transplantation of subcutaneous fat from the 
inguinal region of male donors into the intra-abdominal compartment of male recipient 
mice resulted in significantly protective effects on adiposity, insulin sensitivity and glucose 
tolerance (50-53). Since protective effect of a large hip circumference with regard to 
cardiovascular disease morbidity and mortality is significant in women but not in men (54), 
it would be expected that transplanting female subcutaneous adipose tissue might have 
greater protective effects.  
2.2. Sex hormone estrogens and estrogen receptors regulate adiposity 
Obesity development is accelerated after menopause in women; factors such as loss of 
estrogens, the ageing process and changes in lifestyle may all be contributors (Shi & Clegg 
2009, Barton 2010). The effect of menopause is supported by animal models showing that a 
reduction in circulating estrogen levels following ovariectomy results in increased body 
adiposity (55). Body fat increases in several conditions associated with estrogen deficiency 
such as ovariectomy, polycystic ovary syndrome (PCOS), and the lack of a functional 
aromatase gene; all can be corrected and reversed by exogenous administration of 17β-
estradiol, the active form of estrogens (56-61).  
The classical nuclear estrogen receptors (ER) include estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ).Genomic activation of ERs results from estrogens binding to 
estrogen response elements (EREs) in promoter regions of target genes (62, 63). Increased 
visceral adiposity is associated with the XbaI polymorphism of the human ERα gene when 
guanidine is substituted for adenine in exon one (64). Additionally, pre-menopausal women 
with increased of visceral adiposity, indicated by higher waist-hip ratios, have the XbaI 
polymorphism compared to the control cohort of women with the normal genotype (64). 
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Interestingly such polymorphism does not affect adiposity in postmenopausal women or in 
men(64). ERα gene expression in subcutaneous adipose tissue is reduced in obese pre-
menopausal women, but increases after weight reduction (65). Furthermore several ERα 
single nucleotide polymorphisms have been associated with obesity phenotypes in women 
and men (64, 66, 67). Thus, polymorphisms of the human ERα gene may impair estrogen 
signaling and lead to increased visceral adiposity and its attendant health risks. In humans, 
polymorphisms in the ERβ gene have been associated with lower BMI although other 
investigators found no correlations (68, 69). 
Utilizing targeted deletions in the ERα gene or both ERα and ERβ genes of male and female 
mice indicate increase in adiposity (70, 71). ERβ inhibits food intake and reduces body 
weight through effects in the central nervous system in rats (72). In addition, one study 
investigated the effect of estrogens on adipose tissue development using ERα knockout 
mice. Loss of estrogen following ovariectomy in ERα knockout mice resulted in decreased 
body fat and adipocyte size, which was reversed by 17β-estradiol treatment (73), suggesting 
that regulation of body adiposity is mediated by an ER other than ERα, possibly by ERβ. In 
contrast, mice lacking both ERα and ERβ develop obesity but increased adiposity is not 
observed in ERβ-knockout mice (71), questioning a role for ERβ and suggesting that the 
obesity-promoting effect of estrogen deficiency is mediated specifically through ERα. These 
findings support a substantial physiological role for ERα in mediating the effects of 
estrogens in the control of body adiposity. Replacement of 17β-estradiol prevents 
ovariectomized wild-type mice from developing obesity, such protective effects are not 
observed in ovariectomized ERα deficient mice (74). Therefore, estrogens, together with its 
ERα, play important roles to regulate total adiposity. 
To summarize, the metabolic effects of estrogens appear to be largely mediated by ERα 
whereas the role of ERβ and possible cross-talk with other ERs is currently unclear. Indeed, 
ERβ inhibits ERα-mediated gene expression in certain cell types and often opposes the 
action of ERα (75), an interaction that might be also important for the regulation of body fat. 
Finally, it should be noted that compensatory developmental changes in both animal models 
and humans may alter hormone responsiveness in ways that are different from the inherent 
biology in healthy individuals or wild-type animals respectively.  
2.3. Sex hormone estrogens regulate fat distribution 
Because there are differential effects on health risk between subcutaneous and abdominal 
adipose tissues, it is important to understand mechanisms that determine not only total fat 
accumulation but also where fat is accumulated, and how fat distribution is regulated in 
males and females. Recent research using molecular approaches and animal models has 
provided greater understanding of the role of sex hormones and other molecules on fat 
partitioning. 
The question of sex differences in fat distribution have been examined using animal models. 
Several animal species, including pigs and rodents, show sex-specific differences in fat 
distribution, with males having more abdominal fat and less subcutaneous fat than females. 
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Ovarian hormone estrogen appears to be a key regulator in mediating the sex-specific 
adipose tissue distribution pattern. Estrogens promote the accumulation of subcutaneous fat 
(76). In contrast, abdominal fat varies inversely with levels of estrogens (77). During the 
peri-menopausal period, depletion of ovarian follicles leads to a steady decline in 17β-
estradiol production in post-menopausal women (78). Loss of estrogens with menopause is 
associated with an increase in abdominal fat accrual (36). Indeed, changes in body fat mass 
are positively correlated with serum 17β-estradiol concentration in post-menopausal women 
(79-81), although this association varies with time from the onset of menopause and may 
take up to 6 years to develop (81). In premenopausal women, there is a lower incidence of 
metabolic disorders associated with obesity. However, after menopause when there is a very 
low level of estrogen in the circulation, an increased risk of obesity-related metabolic 
disorders is reported (38). Therefore ovarian hormones might play a vital role in protecting 
the body against metabolic diseases via the sex-based differences seen in adipose tissue 
deposition.  
The sexual dimorphism in adipose tissue distribution may partially explain the greater risk 
for the metabolic syndrome in men compared with premenopausal women. Estrogens are 
known to regulate body fat distribution in animals and humans. As being discussed earlier 
in this chapter, females tend to accumulate more fat in their subcutaneous depots whereas 
males tend to accumulate more fat in their visceral depots (82). Additionally, after the loss of 
endogenous estrogens as a result of menopause, a shift towards visceral adiposity occurs, 
which is sensitive to estrogen therapy (55).  
Studies in ovariectomized rodent models have elucidated possible mechanisms by which 
changes in estrogen levels may impact fat distribution. Ovariectomized female rats gain fat, 
specifically visceral fat with a loss of subcutaneous fat (19, 83). Additionally peripheral or 
central administration of 17β-estradiol to OVX rats changes their body fat distribution to 
mirror that of intact females with normal estrous cycles. administration of exogenous 
estradiol reverses this increased visceral fat distribution pattern (19). Furthermore, altering 
the sex hormone milieu in males with exogenous 17β-estradiol administration to male rats 
decreases visceral fat and increases subcutaneous fat relative to males not given estrogen 
(19). An important implication from these findings is that estrogens are critical determinates 
of body fat distribution. Estrogen may influence fat distribution centrally by modulating 
leptin responsiveness, as leptin not only influences total body fat in rodents but also favors 
loss of visceral fat via Stat3 signaling in the hypothalamus (84). Female mice are more 
responsive than male mice to the effects of centrally administered leptin to decrease food 
intake and body weight and to increase c-fos and Stat3 expression in the arcuate nucleus 
(85). In addition, research has shown that both male and female aromatase-knockout mice, 
which are estrogen-deficient and have elevated testosterone, accumulate more abdominal 
adipose tissue with increased adipocyte size in the gonadal and intra-renal fat depots (57). 
Male aromatase-knockout mice also develop fatty liver, as do aromatase-deficient men, and 
this is reversible with estradiol treatment (86). 
Sex hormones play important roles in adipose tissue lipolysis and fat uptake. Sex differences 
exist for regulation of lipolysis by alpha-2 adrenergic receptor(87). Estrogen treatment 
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increases lipolysis in abdominal fat cells in mice(88). Lactation and menopausal status also 
impact the lipolytic responsiveness and lipoprotein lipase activity of fat cells. Higher 
adipose tissue lipoprotein lipase activity (promoting fat storage) occurs in subcutaneous 
femoral adipocytes compared with abdominal adipocytes in premenopausal women but not 
in postmenopausal, estrogen-deficient women(89). Additionally lipolysis increases in 
subcutaneous femoral fat during lactation but not in abdominal fat(89). Furthermore, 
estrogen treatment in postmenopausal women restores the lipoprotein lipase activity of the 
femoral adipocytes and attenuates lipolytic response in subcutaneous adipocytes but not in 
abdominal adipocytes (90). Subcutaneous gluteal adipocytes from premenopausal women 
are more sensitive to the antilipolytic effects of insulin than abdominal adipocytes (91). 
Testosterone, male androgens also impact body fat distribution. Testosterone deficiency 
aggravates the development of obesity and hyperinsulinemia, which in turn will suppress 
testicular androgen synthesis even further and result in a vicious cycle (92). In ‘andropause’ 
men, gradual decline in circulating androgens with aging is accompanied by increased total 
and abdominal fat (93). Administration of aromatizable androgens such as testosterone (94, 
95), but not nonaromatizable dihydrotestostone (94), reduces total and abdominal fat in 
older men. In contrast, androgen administration to ovariectomized female mice significantly 
increases body adiposity and abdominal fat (96). Such obesity development is associated 
with reduced fatty acid oxidation, indicated by decreased phosphorylation of adenosine 
monophosphate (AMP)-activated protein kinase and acetyl-CoA carboxylase in abdominal 
visceral fat (96). In humans, women with higher circulating androgen levels (97) or 
exogenous androgen administration (98, 99) increase abdominal fat. These findings raise 
significant clinical concern about the use of testosterone as a hormone replacement therapy 
in postmenopausal women.  
In summary, sex differences in body fat distribution appear to be largely a result of 
differences in sex hormones between men and women. Estrogens reduce visceral fat in men 
and women, an effect that is likely mediated by both central and peripheral mechanisms. In 
contrast, opposite effects of androgens on fat distribution in men and women are seen, with 
aromatizable androgens decreasing visceral fat in men but increasing it in women. 
2.4. Estrogen receptors regulate fat distribution 
Gonadal hormones, including estrogen, progesterone and androgen, have their receptors 
expressed in the visceral and the subcutaneous adipose tissue depots (100). Subcutaneous 
adipose tissues have higher concentrations of estrogen receptors and progesterone receptors 
than androgen receptors in females, and estrogens down-regulates AR expression in 
subcutaneous fat (101). In contrast, visceral adipose tissue has higher concentrations of 
androgen receptors (102, 103). In visceral adipose tissue, there is an increase in the 
expression of androgen receptors in males relative to estrogen receptors. The development 
of knockout animals has provided a powerful tool to examine the role of individual 
receptors for estrogen, progesterone and androgen in the regulation of adipose tissue. 
Adipose tissue-specific androgen receptor knockout mice have increased intra-adipose 
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tissue estradiol levels, which precedes increased subcutaneous obesity and hyperleptinemia 
(104). Additionally, androgens can be converted to estrogens through activation of the 
aromatase enzyme. Aromatase knockout mice have elevated testosterone and accumulate 
more abdominal adipose tissue with increased adipocyte size in the visceral fat depot. 
Hence, in adipose tissue, there is a counteracting effect between estrogen and androgen, 
which may lead to differences in fat distribution.  
Estradiol regulates body fat distribution either directly at the level of the adipocyte or 
through augmenting the efficacy of the adiposity signals in the CNS. Subcutaneous and 
abdominal adipose tissues express both ERα and ERβ, but ERα is predominantly expressed 
in abdominal adipose tissue (105) and ERβ are higher in subcutaneous adipose tissue (106). 
ERα gene polymorphisms predict abdominal obesity in women, but not in men, suggesting 
a possible sexual dimorphism in the ERα effects (64). Female and male mice lacking ERα 
develop central obesity with increases in abdominal adipose tissue, which is reflected by 
increased adipocyte number and size (70). ERα is ubiquitously expressed in rodent brains, 
but the physiologically relevant sites of ERα in the regulation of food intake and energy 
expenditure have not been identified. ERα is expressed in the ventrolateral portion of the 
VMN, the ARC, the medial preoptic area (MPOA), and the paraventricular nuclei (PVN) 
(107-109). ERβ is found in the same hypothalamic nuclei as ERα, but ERβ expression is 
significantly reduced relative to ERα. Site-specific knock-down of ERα in bilateral 
ventromedial nucleus of the hypothalamus in mice using siRNA result in increased 
adiposity, no change in food intake, and suppression of energy expenditure, increased 
visceral adiposity, and decreased leptin sensitivity, implicating ventromedial hypothalamic 
ERα in energy homeostasis (110).  
Both short-term and long-term castration in males resulted in increased insulin sensitivity and 
increased lipogenesis in both abdominal and subcutaneous adipose tissues, an event that is 
independent of changes in the fat pad weights (102). Thus, in contrast to the preferential effect 
of estrogen in females on the abdominal adipocytes, testosterone exerts an inhibitory effect on 
lipogenesis and insulin sensitivity in both abdominal and subcutaneous adipocytes. 
3. Sex difference in glucose metabolism 
Glucose challenge test is important in terms of understanding the pathophysiology of 
individuals at risk of progressing to type 2 diabetes. As recommended by the World Health 
Organization, the standardized, 75-g oral glucose tolerance test is used for diagnosis of 
impaired fasting glucose and impaired glucose tolerance. Plasma glucose at fasting and 2 
hours after oral glucose tolerance test are measured to indicate glucose tolerance in 
individuals. Fasting glucose is the glucose concentration after an overnight fast and mostly 
reflects endogenous glucose production, whereas glucose level 2 hours after oral glucose 
tolerance test, i.e. post-load hyperglycemia, reflects the acute increase in blood glucose after 
a glucose challenge. 
Several epidemiological investigations from European countries (111-113), Australia (114-
116), Asian countries (117), and Mauritius (118) report that men have higher fasting plasma 
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glucose levels and plasma glucose levels during the early course of the oral glucose tests 
than women, indicating that the prevalence of impaired fasting glycaemia is higher in men 
than in women; and  women have higher plasma glucose levels 2 hours after oral glucose 
tolerance tests than men, suggesting that the prevalence of impaired glucose tolerance is 
higher in women than in men. The pre-diabetic condition of impaired fasting glycaemia is 
characterized by hepatic insulin resistance, elevated hepatic glucose production and beta 
cell dysfunction.  
3.1. Sex difference in glucose tolerance  
Men and women are given the same amount of glucose during a standard oral glucose 
tolerance test. In all ethnic groups throughout the world, women are on average shorter by 
approximately 15 cm and thus have smaller body sizes than men (119). Additionally, 
women generally have less absolute amount of fat-free muscle mass than men, which is the 
major metabolically active tissue involved in glucose uptake, and thus women are less able 
to metabolize the fixed amount of glucose (111, 115, 118). The higher prevalence of impaired 
glucose tolerance in women may be an artifact caused by the fact that individuals of 
different body sizes and lean muscle masses receive the same amount of glucose during 
glucose challenge test. This notion is supported by the observation that the increments of 
glucose, insulin and the incretin hormones glucagon-like peptide-1 and glucose-dependent 
insulinotropic polypeptide after an glucose challenge test are significantly higher in women 
than in men (120), indicating that the same amount of glucose represents a larger stimulus in 
women than in men when seen in relation to their body sizes. 
Further analysis using anthropometric measures (e.g., weights, heights and waist-hip 
circumferences) indicated that the differences in plasma glucose levels 2 hours after oral 
glucose tolerance tests, but not  fasting plasma glucose levels, could be explained by 
differences in body size and/or body composition between men and women (113, 115, 118, 
121). Consequently, women are more commonly diagnosed with diabetes on the basis of 
glucose level 2-hour post glucose tolerance test compared with fasting plasma glucose levels 
(112, 115).The risk of gestational diabetes is also higher in shorter compared with taller 
women (122). Women do not have higher glucose levels following glucose test than men 
when differences in height and high-waist circumference (113) or absolute amount of fat-
free mass (121) are taken into account. This notion is supported by the observation that there 
is a higher risk of developing type 2 diabetes in men than in women with impaired glucose 
tolerance (123), suggesting that women with impaired glucose tolerance may be healthier 
than their male counterparts. In summary, sex difference in glucose tolerance without taking 
into account of body size is probably not related to sex-specific differences in the physiology 
of glucose regulation. 
3.2. Sex difference in fasting plasma glucose 
In contrast to the sex difference in glucose tolerance, sex difference in fasting plasma glucose 
levels is not related to differences in anthropometry and could not be explained by 
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differences in body size and/or body composition between men and women. Indeed, higher 
fasting plasma glucose in men compared with women reflects differences in insulin 
sensitivity and pancreatic β cell function between men and women (113), suggesting that the 
sex difference in fasting plasma glucose has a true physiological basis.  
During fasting females have decreased liver enzymes, lower creatinine and uric acid 
concentrations with a trend toward reduced triglycerides, but higher HDL cholesterol and 
body fat mass, which are generally seen as gender-related differences because of the direct 
effects by sex hormones (124, 125). There is an association between elevated FFA and 
increased endogenous glucose production (126). Interestingly, females displayed lower 
fasting endogenous glucose production than males, despite higher fasting plasma FFA 
concentrations (116). Study using laboratory rodent models indicate that there is no direct 
effect by FFA on hepatic glucose production in isolated perfused rat liver (127).  
The possible physiological mechanism that is responsible for the higher fasting plasma 
glucose levels observed in men compared with women could be related to large waist 
circumference in men (128), suggesting that sex differences in body fat distribution 
contribute to the sex difference in fasting plasma glucose levels. Indeed, high waist 
circumference and hip circumference are associated with impaired glucose tolerance in both 
men and women (113), suggesting that obesity contributes and is related to disturbances of 
glucose metabolism. Visceral component of abdominal fat is strongly associated with insulin 
resistance (129). Abdominal adipose tissue has a reduced ability to metabolize the glucose 
load of a glucose challenge test (102). Homeostasis model assessment of insulin resistance 
(HOMA-IR), predominantly reflecting hepatic insulin resistance, is lower in men than in 
women in general (113). Homeostasis model assessment of β cell function (HOMA-β) is also 
slightly lower in men than in women.  
In summary, sex differences in fasting plasma glucose levels are caused by underlying 
physiological differences in both insulin sensitivity and β cell function.  
3.3. Sex difference in glucose absorption 
Sex difference in carbohydrate metabolism may contribute to sex-specific glucose 
regulation. A glucose infusion at fasting and during hyperinsulinemia is used to measure 
whole-body insulin sensitivity and endogenous glucose production using hyperinsulinemic 
clamp technique. Healthy glucose-tolerant women have slower glucose absorption rates and 
slower liquid emptying from the stomach (130), and thus longer gut glucose half-life 
compared with glucose-tolerant men(116).Furthermore, there is an association between 
glucose absorption velocity and body size, with body tallness having strong influence on the 
glucose absorption velocity. This notion is supported by a recent study showing that, for 
both sexes, although people with different heights have similar fasting glucose levels, those 
in the shortest height quartile do have significantly higher 2 h glucose levels following oral 
glucose tolerance test compared with those in the tallest height quartile (115). As it is 
mentioned earlier in this section, women are on average shorter by approximately 15 cm 
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than men (119). Consequently, women generally have lower glucose absorption rates and 
have higher plasma glucose levels 2 hours after oral glucose tolerance test than men (115).  
Glucose absorption rates are higher in males in the initial phase and elevate in females in the 
end of the of the oral glucose tolerance tests three hours after oral glucose intake (116). The 
best-suited value to describe of glucose absorption velocity is glucose half-life in the gut. In 
all participants, glucose half-life is negatively related to body height and fat-free mass (116, 
131), thus glucose half-life is prolonged in females in comparison with males. When 
adjusted for total fat-free body mass, females with similar gut absorption as males are 
slightly more insulin sensitive than males(116). The alterations of plasma glucose 
concentrations during glucose tolerance test in females and males are not only due to 
different glucose clearance rates but also due to  different absorption rates from the 
gastrointestinal tract between sexes (116), which could serve to explain higher glucose 
concentrations at the end of the glucose challenge test in females. Additionally, postprandial 
insulin secretion affects glucose disappearance rate and glucose concentrations. One study 
has reported that females have greater peripheral insulin release and thus higher 
concentration during the first hour of oral glucose tolerance test (132). A separate study has 
reported that insulin secretion is comparable between young males and females following a 
high-carbohydrate mixed meal (133). Therefore, these available data from previous human 
studies suggest that the disturbance in insulin secretion does not contribute to the higher 
postprandial glucose concentrations in women. This notion is supported by animal studies 
using rodents, which have reported no sex associated difference in glucose-stimulated 
insulin secretion (134).  
To summarize, sex difference in glucose absorption and concomitant effect of insulin 
release, but not insulin-induced glucose uptake or glucose metabolism, contributes to the 
higher prevalence of glucose intolerance in females diagnosed from oral glucose tolerance 
tests as observed in several epidemiological studies worldwide. 
4. Sex differences in insulin sensitivity 
Glucose homeostasis is maintained in a narrow range via glucose output by the liver and 
glucose uptake by tissues. Insulin, secreted by the pancreatic β cells in response to increased 
circulating levels of glucose, is the major anabolic hormone whose action is essential for 
maintenance of glucose homeostasis. Insulin regulates glucose homeostasis by reducing 
hepatic glucose production via decreased gluconeogenesis (de novo glucose synthesis) and 
glycogenolysis (glycogen breakdown), and increasing the rate of glucose uptake, primarily 
into skeletal muscle and adipose tissue (135). Insulin's actions are brought about by 
intracellular events following the binding of insulin to insulin receptor and the activation of 
its tyrosine kinase, which phosphorylates tyrosine residues of target proteins such as insulin 
receptor substrates (136). The phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade is 
activated by the IRS proteins to trigger the stimulation of glucose uptake (135). Insulin 
resistance, defined as a state of decreased responsiveness of target tissues to insulin, plays a 
major role in the development of type 2 diabetes. Increased plasma free fatty acid 
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concentrations due to high-fat diet feeding are typically associated with many insulin-
resistant states (135).Abnormalities in fatty acid metabolism result in inappropriate 
accumulation of lipids in myocytes and hepatocytes, thus impairing their function and 
leading to insulin resistance (135). 
4.1. Female human and animals are more insulin sensitive 
There is evidence indicating that insulin sensitivity differs between males and females (137). 
Premenopausal women have better glucose tolerance and insulin sensitivity compared with 
men in general. Despite having lower fat mass, the prevalence of diabetes and early 
abnormalities of glucose metabolism is three times higher in men than in women (138). 
Moreover, women have decreased susceptibility to fatty acid–induced peripheral insulin 
resistance (124, 139, 140). Female humans and rodents are more insulin-sensitive than their 
male counterparts.  
In many different laboratory rodent models of glucose intolerance, insulin resistance, and 
diabetes, the different insulin sensitivity of female versus male mice can be detected by 
glucose tolerance tests and insulin tolerance tests. When various strains of mice are 
subjected to glucose tolerance tests, female mice have lower glucose levels than male mice at 
different time point throughout the tests (141-143). Additionally, female mice show a  
greater fall in blood glucose in response to insulin as compared with male mice during 
insulin tolerance tests (141-143). These data from our lab suggest that female animals are 
more insulin sensitive than males. Furthermore, female rodents are less prone to diet-
induced insulin resistance, and many genetically induced forms of insulin resistance have a 
milder phenotype in females compared with males (141, 142, 144, 145).  
4.2. Female fat cells are more insulin sensitive 
Adipocytes in different fat depots appear to have a distinct impact in insulin sensitivity. As 
it is mentioned previously in this chapter, accumulation of visceral fat, but not subcutaneous 
fat, is linked to the development of metabolic complications. Fat accumulation in different 
depots is sexually dimorphic, i.e., men accumulate more visceral fat, whereas women 
accumulate more subcutaneous fat and have a higher percentage of body fat compared with 
men. These sex-related differences in insulin sensitivity and adipose tissue development and 
function could be attributable in part to actions of estrogen and testosterone. For example, 
decreases in estrogen and increases in testosterone levels that occur during menopause are 
associated with loss of subcutaneous and gain of visceral fat and increase in insulin 
resistance (146).  
Female adipocytes have increased insulin sensitivity compared with male adipocytes, which 
is particularly true for abdominal adipocytes (102, 147). A recent study analyzed insulin 
sensitivity and glucose metabolism of adipocytes from abdominal and subcutaneous 
adipose tissue from normal, castrated, or steroid-implanted mice (102). The authors reported 
that both abdominal and subcutaneous adipocytes of females have greater lipogenic rates 
than those from males. Additionally, female abdominal adipocytes are more insulin 
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sensitive than subcutaneous adipocytes and more insulin-sensitive than male adipocytes 
from either depot, with female abdominal adipocytes showing a robust increase in insulin-
induced lipogenesis and insulin signaling, including downstream targets Akt and 
extracellular signal–related kinase phosphorylation, when stimulated by low physiological 
concentrations of insulin. In contrast, male adipocytes show activation only at much higher 
insulin concentrations (102). Furthermore, adipocytes from females have higher mRNA and 
protein levels of several genes involved in glucose and lipid metabolism, including glucose 
transporters and key lipogenic enzymes fatty acid synthase and acetyl CoA carboxylase 
(102), suggesting that the sex difference in insulin sensitivity at adipocyte level is 
attributable at least partially to increased glucose transporters and lipogenic enzyme levels. 
In summary, sex-specific differences in insulin action in adipocytes may contribute to the 
sexual dimorphism of insulin resistance.  
Despite a higher lipogenic rates female adipocytes are smaller than male adipocytes, 
especially those from the abdominal adipose depot. This is because adipocytes of females 
also has a higher lipolytic capacity than those of males (148, 149), suggesting a higher 
metabolic turnover of female abdominal adipocytes leading to decreased fat accumulation 
in visceral depots in females compared with males. As a result, in humans, females have 
higher serum levels of free fatty acid than males (124, 139) but appear to be protected 
against insulin resistance induced by elevated free fatty acid (139).  
Sex steroids are known to play a role in the regulation of adipose tissue development and 
function as well as whole body insulin sensitivity (146). These sex differences in insulin 
sensitivity in adipose tissue are regulated by physiological levels of sex steroids. Adipocytes 
of castrated male mice have increased insulin sensitivity and increased lipogenic rates, 
whereas adipocytes of ovariectomized females have lowered insulin sensitivity and reduced 
lipogenic capacity (102). The increased sensitivity to insulin and lipogenesis observed in 
adipocytes from females may account for their lower level of insulin resistance and diabetes 
risk despite similar or higher fat content than in male mice (102), indicating a positive role of 
estrogen in insulin sensitivity and lipogenesis in females. Therefore, gonadal hormones 
estrogen and testosterone contribute to the sexual dimorphism of lipogenesis and insulin 
sensitivity, lipogenic capacity of adipocytes.  
4.3. Estrogens regulate insulin sensitivity  
Gonadal hormones play critical roles in the regulation of glucose metabolism and 
maintenance of insulin sensitivity. Disturbances and changes in the relationship between 
estrogens and androgen metabolism seem to adversely affect fat metabolism and insulin 
sensitivity independent of sex (see below). Deficiency of estrogen leads to development of 
insulin resistance. Animals and humans lacking endogenous estrogen synthesis exhibit 
insulin resistance, which can be treated by estrogen supplementation (57, 61, 150). In 
humans, postmenopausal women with deficiency in endogenous estrogen have increased 
risk of insulin resistance and developing type 2 diabetes (4), while hormone replacement 
therapy or treatment with estradiol, the major bioactive form of estrogen, improves insulin 
sensitivity and lowers blood glucose levels (151, 152) and reduce incidence of diabetes (153, 
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154). Insulin resistance in a man with a homozygous inactivating mutation of the aromatase 
gene has been reported (60, 155). Estrogen deficiency also contributes to the development of 
insulin resistance and type 2 diabetes in rodent models (Louet et al 2004). Ovariectomized 
rodents with low level of endogenous estrogen have elevated basal glucose levels and 
impaired glucose tolerance (Bailey et al 1980). Aromatase knockout mice with a genetic 
impairment in endogenous estrogen synthesis exhibit decreased glucose tolerance and 
insulin resistance (Jones et al 2000; Takeda et al 2003).  
The mechanism of regulation of estrogens on insulin sensitivity is not clear. Estrogens may 
increase hepatic insulin sensitivity by decreasing gluconeogenesis and glycogenolysis and 
increasing insulin release in islets of Langerhans (156). Estrogens also prevent β-cell 
apoptosis (157). Additionally, estrogens reduce pro-inflammatory adipokines and their 
signaling and therefore decrease inflammation (158, 159). Changes in the level of sex 
steroids had variable effects on levels of circulating adipokines, as ovariectomized females 
have lower level of adiponectin and females implanted with estradiol have higher 
adiponectin levels (102). It is increasingly evident that chronic activation of pro-
inflammatory pathways may be at least partly responsible for obesity-induced insulin 
resistance and diabetes (25, 160). ERs are expressed in monocytes and macrophages, and 
estrogens activate these cells (161, 162). Female rats and mice are relatively protected from 
high-fat diet induced obesity, insulin resistance and inflammatory responses (141-143, 163-
165). Recent studies have shown that 17β -estradiol may play a role in reducing the 
inflammatory response in adipose, cardiovascular, and neural systems (146). Suppression of 
pro-inflammatory responses with estrogens may represent a promising strategy to combat 
obesity and associated metabolic disorders. Furthermore estrogens may improve insulin 
action (166). Therefore, the greater amount of abdominal visceral adipose tissue in 
conjunction with lower endogenous estrogen levels found in men may be related to the 
higher insulin resistance when compared with pre-menopausal women.  
4.4. Estrogen receptor regulates insulin sensitivity  
Estrogen’s action is via its classic nuclear receptors and non-classic membrane receptors (63, 
167-172).Both ERα and ERβ are expressed in the liver, muscle, and adipose tissue, as well as 
in several key regions of the hypothalamus of the central nervous system that have been 
linked to the control of peripheral glucose homeostasis. In particular, recent evidence points 
to neurons in the arcuate nucleus as critical regulators of glucose homeostasis (173). ER 
subtype-specific ligands have been used to clarify the specific roles of ERα and ERβ, such as 
the selective ERα ligand propyl pyrazoletriol (PPT) and the selective ERβagonist (2,3-bis(4-
hydroxyphenyl)-propionitrile (DPN). PPT has similar effects as estradiol, including increase 
of uterine weight, and prevention of increased body weight following ovariectomy (174). In 
addition, estrogen acts through other extranuclear pathways after ligands bind to the ERα or 
ERβ associated to the plasma membrane, as well as to ERs located at the plasma membrane, 
in the cytosol, or in the mitochondria (167, 171, 175) to regulate energy balance and glucose 
homeostasis (167). Estrogen may trigger its actions after binding to membrane ERs, such as 
GPR30 (176, 177), binding to receptors for other ligands, or binding to ion channels (167, 178, 
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179). The membrane ERs are characterized by a completely different pharmacological profile 
when compared to nuclear ERα and ERβ. They do not bind the antiestrogen ICI182,780 (167). 
These extranuclear actions of estrogen are the rapid activation of signaling cascades resulting 
in the activation of transcription factors and therefore in the regulation of gene expression.  
Both animal and human studies suggest that ERα may play a critical role to regulate glucose 
tolerance and insulin sensitivity (see below). Impaired insulin sensitivity, glucose 
intolerance, and hyperinsulinemia in a man with a mutation of ERα and thus lacking 
functional ERα has been reported (180). Estrogen-dependent effects on glucose homeostasis 
through both ERα and ERβ, whereas glucose tolerance is normal in ERβ-knockout mice (70, 
73, 181, 182). Additionally, ERα deficiency increases fasting insulin levels, impairs glucose 
tolerance, and results in skeletal muscle insulin resistance (182), suggesting that ERα may 
have a direct anti-diabetic role. Insulin sensitivity is preserved in mice lacking ERβ although 
these animals become obese following a high-fat diet (183). In addition, ERβ acts as an 
inhibitor of peroxisome proliferators-activated receptor gamma activity, a major inhibitory 
regulator of glucose and lipid metabolism (183). Therefore, previous studies argue in favor 
of an estrogen-dependent regulation of glucose tolerance and insulin sensitivity by ERα. 
Several mechanisms of metabolic function of ERs involved in the regulation of estrogen-
mediated insulin sensitivity have been suggested by animal studies.  
First, estrogen’s action helps to sustain insulin production. In the absence of ERα, 17β-estradiol 
only partially protects pancreatic β-cells from apoptosis in diabetic male and female mice 
(157), suggesting that this effect is at least in part ERα dependent. A recent study from the 
same group of investigators has demonstrated that estradiol stimulates islet insulin synthesis 
in an ERα independent manner, through interactions between non-classic extranuclear / 
membrane ERα and the tyrosine kinase Src, which activates ERK1/2 MAPK (184).  
Second, estrogen’s action facilitates insulin release. Glucose- and arginine-stimulated insulin 
release in pancreatic islets is similar in mice lacking either ERα or ERβ when compared with 
control animals (181).17β-estradiol does not increase insulin levels in isolated islets from 
ERαknockout animals compared to controls or to ERβ-knockout mice (156).  
Third, estrogen’s action regulates insulin sensitivity in liver and muscle. The development of 
ERα and ERβ knockout mice (185) has demonstrated the participation of these receptors in 
the regulation of many processes related to glucose metabolism, including insulin sensitivity 
in the liver and muscle. Impaired insulin sensitivity and glucose tolerance as determined by 
the hyperinsulinemic clamp technique in ERα deficient animals is attributed to either 
inadequate suppression of hepatic glucose production by insulin or impaired insulin action 
in skeletal muscle (181, 182).Furthermore, insulin-stimulated glucose uptake in skeletal 
muscle, mediated by the glucose transporter isoform GLUT4, is suppressed in the absence of 
ERα (181), however GLUT4 expression is not affected in mice lacking ERβ (186).  
Fourth, estrogen’s action mediates inflammation associated with insulin resistance. In both 
healthy and diabetic mice lacking ERβ, 17β-estradiol reduces inflammatory nitric oxide 
synthase expression in the aorta. This inhibitory effect is absent in ERα knockout animals 
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(187), indicating that the protective effects of estrogens on inflammatory responses in the 
vessel wall are mediated by ERα (187). In addition, adiponectin, an adipokine associated 
with suppression of insulin resistance and inflammation, is decreased in the absence of ERα 
whereas plasminogen activator inhibitor-1, a surrogate marker of systemic inflammation is 
increased (182). Increased inflammation-associated changes following streptozotocin-
induced injury of pancreatic islets have been described in ERα-deficient mice (Le May et al. 
2006). Moreover, enhanced inflammatory signaling and impaired fatty acid oxidation are 
found in the skeletal muscle of ERα-knockout mice (182), further indicating an ERα 
dependent regulation in inflammation which affects insulin resistance. In vitro studies have 
demonstrated 17β -estradiol-activated ERα decreases the number of pro-inflammatory 
cytokines (161). The anti-inflammatory properties of 17β-estradiol can be partially explained 
by the ability of ERs to act as transcriptional repressors by inhibiting the activity of nuclear 
factor kappa B (NFκB) through protein–protein interactions between agonist-bound ERs and 
activated NFκB subunits (188-190). Estrogens' inhibitory effect on NFκB function is not fully 
understood and may be target selective (189, 191). The PI3K pathway is also implicated in 
the anti-inflammatory effects of estrogens. For example, 17β-estradiol blocks LPS-induced 
NFκB nuclear translocation in macrophages, an effect that involves the activation of PI3K 
(188). Similarly, estradiol-17β decreases vascular leukocyte accumulation after an ischemia–
reperfusion injury, and these effects are blocked by PI3K inhibitors (192) 
In summary, previous studies not only support that estrogens and their cellular targets are 
important for the maintenance of glucose homeostasis, but also indicate an important role of 
ERα in the regulation of insulin sensitivity.  
5. Conclusion 
Sex differences and the role of gonadal hormones in modulating insulin sensitivity and 
glucose tolerance are of increasing interest and importance because of the increasing 
prevalence of type 2 diabetes mellitus and the metabolic abnormalities. Body composition is 
closely associated with insulin sensitivity, and increased body fat, particularly in the visceral 
compartment, is a risk factor for developing type 2 diabetes mellitus. Sex differences in body 
composition and/or insulin sensitivity are evident in humans and many non-human animal 
models. 
Gonadal hormones estrogens and androgens are important, sex-independent regulators of 
body weight, body fat distribution, glucose metabolism and insulin resistance. When 
women enter menopause, they have a dramatically increased risk for developing obesity, 
type 2 diabetes and the metabolic syndrome. Although conventional hormone replacement 
therapy might beneficially to affect adiposity and to reduce diabetes risk, its previous use in 
women is associated with adverse effects including an increased risk for breast cancer and 
heart disease (i.e. thromboembolism). This increased risk may partly due to non-selective 
activation of ERs, which are ubiquitously expressed in the human body, especially in 
peripheral tissues, and due to complex intracellular events coupled to ERs genomic and 
non-genomic actions.  
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Future basic science investigations should therefore lead to a better understanding of the 
molecular mechanisms whereby different ERs regulate body weight, body fat, and insulin 
sensitivity in both females and males. Important gaps in the research need to be identified. 
In particular, potential interactions and cross-talk between ERα and G-protein-coupled 
estrogen receptor, which seem to mediate most beneficial effects, critical brain sites where 
ERs regulate glucose homeostasis, and intracellular signaling pathways that are required for 
estrogens' actions, need to be identified. Consequently only the ERs involved in energy 
homeostasis and glucose metabolism will be targeted. This identification would help to 
define novel pharmacological targets selectively associated with fat metabolism and glucose 
homeostasis and help to develop estrogen-like drugs that only initiate intracellular events 
that produce metabolically beneficial actions without deleterious side effects. Such an 
approach would also imply a therapeutic potential in men bypassing the unwanted effects 
of estrogens. 
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